Dermatology OPD Records: Lesion Maps, Photos and Clear Regimens
Connect lesion descriptions, clinical photographs and site-specific skin treatment instructions in a practical workflow for Indian dermatology clinics.
An isotretinoin follow-up record should connect the current prescription, pregnancy-risk assessment where relevant, confidential symptom review, investigation interpretation and the dermatologist's decision. A normal laboratory result or completed questionnaire is not automatic permission for another prescription. Preserve the patient's actual exposure and concerns, and make the next review and urgent-contact instructions clear.
Indian dermatology clinics coordinating isotretinoin consultations, investigations, counselling, prescriptions and pharmacy questions.
Identify the indication, prescribing clinician, current product and authorised instructions. Record when treatment started and any later change, with its effective date. An active medicine row can remain in a system after the real plan has changed, so it should not be the sole source for a repeat order.
Separate four events: a review becomes due, information is collected, the clinician assesses it, and a prescription is issued or another action is chosen. The same patient may be ready for an appointment while still having an unresolved concern. A green 'labs uploaded' status should not collapse the remaining decisions.
Make the reason for today's decision understandable. The note should explain the relevant response, tolerability, concerns and evidence the dermatologist considered. It need not repeat a long generic risk paragraph at every visit if the actual discussion and changes are recorded clearly.
This guide supplies no initiation dose, cumulative-dose target or fixed laboratory interval. Those choices belong to the clinician using the applicable product information, current evidence and the patient's circumstances.
The MHRA's January 2026 UK update continues to emphasise pregnancy prevention and assessment of mental-health and sexual-function concerns during isotretinoin care. It also removed the earlier UK requirement for agreement from a second prescriber for patients under 18. These are dated UK regulatory details, not requirements to copy into an Indian clinic's legal checklist.
The practical record should identify which safety information was explained, the patient's questions and any change since the previous visit. A copied 'risks explained' statement does not show whether the patient raised a new symptom or misunderstood an important instruction.
Pregnancy-related assessment and prevention instructions must follow the responsible specialist's plan and the applicable product information. Record the actual evidence and date where testing or another assessment is required. A historical negative result is not automatically current evidence for a later decision.
A suspected pregnancy or a significant new adverse-effect concern needs prompt contact with the prescribing team and appropriate clinical assessment. It should not wait in an ordinary refill queue. Administrative staff must not invent a continue, stop or restart instruction to make the workflow proceed.
Source: MHRA: Isotretinoin prescribing and risk-minimisation changes (January 2026)
Ask about relevant symptoms and concerns respectfully, with an appropriate opportunity for a private conversation. A parent or partner answering every question may not represent the patient's own experience. Record the source of information and the clinician's assessment without assuming that silence means absence of a concern.
A questionnaire can support the conversation but should retain its name, date, responses and limitations. A score is not a diagnosis and a missing response is not a normal response. The clinician decides what follow-up assessment is needed.
Explain how the patient can contact the team between visits and what to do if the clinic is unavailable. Do not make a public-facing appointment reminder disclose intimate history or pregnancy-related information to a shared family phone.
For younger patients, follow the clinic's appropriate consent, confidentiality and safeguarding processes. This article does not resolve the legal requirements for a particular minor's treatment. The record should show who participated and what was explained without treating a generic signature as the entire process.
Record the clinician-selected monitoring plan, including which investigations are required, their intended timing and who reviews them. Lipid and liver-related results may be relevant to the specialist's plan, but one fixed panel and interval should not be imposed on every patient by a template.
Preserve sample date, result date, units, reference information and relevant preparation or medicine context. A result taken before a dose change may not answer the same question as a result after it. The reviewing clinician should see the timeline rather than only the most recently uploaded PDF.
Separate a received result from an interpreted result. If a value needs clarification, repeat assessment or another clinical action, record that decision and its owner. A software flag that says 'within range' should not independently authorise treatment.
Use the table below to inspect evidence completeness. It is an original coordination model, not a set of clinical eligibility criteria.
On a narrow screen, scroll the table horizontally to read all columns.
| Information domain | Evidence available | Decision still owned by the clinician |
|---|---|---|
| Current prescription | Verified product, instructions and dated changes | Whether that plan remains appropriate |
| Actual exposure | Patient-reported use, interruptions and outside changes | What the exposure means for today's assessment |
| Confidential concerns | Patient account and any structured assessment | Clinical significance and necessary response |
| Investigations | Matched report, sample time and context | Interpretation and whether more information is needed |
| Pregnancy-related plan | Applicable assessment and documented instructions | Current clinical suitability and next required action |
| Review completion | Assessment and communicated plan | Prescription, change, deferral or referral as individually decided |
Ask how the medicine was actually taken, including interruptions, unplanned changes and any supply from another prescriber. Keep the report attributable. A pharmacy issue or payment establishes a supply event; it does not establish ingestion.
In a fictional 14-day review window, a patient reports taking the medicine on 12 days and missing two. The record should preserve those dates and reasons if known. It should not silently count 14 days of exposure because that quantity was issued, or label a calculated percentage as a clinical outcome.
If the dermatologist uses a cumulative-exposure calculation, its inputs must match the actual authorised and reported history, including changes and uncertainty. The calculation should be inspectable, not a hidden number that triggers an automatic continuation rule. This article does not provide a dose target.
Reconcile a new brand or strength before updating the patient instructions. Similar packaging or the same capsule count does not establish the same daily dose. If the patient cannot identify the product, retain the uncertainty and obtain appropriate clarification.
The completed review should state the clinician's decision and the instruction effective from a specific date. If the plan is deferred pending a concern or missing evidence, explain what needs to happen next and who is responsible. Do not convert a deferred prescription into a routine automatic reminder to purchase medicine.
Give the patient an understandable summary of the current instruction, relevant supportive care selected by the clinician, the next review and the route for a new concern. Advice about dryness or lip care should match the actual assessment; it should not dominate the sheet while more consequential instructions are hidden.
Ask the patient to explain any changed instruction and identify the next required action. A new chart is less useful if the family continues using an older screenshot. Mark the current version clearly and keep the previous one as historical evidence.
The following original outline can guide that closing conversation without serving as a prescription or a claim of regulatory compliance.
Use fictional data with a normal-looking laboratory report but a new patient concern. The demonstration should show how the concern reaches the dermatologist and how the review can remain incomplete without producing a prescription. A lab-status badge must not overrule the clinical decision.
Then add an interruption and an outside product change. Ask the operator to distinguish issued quantity from actual-use history and show which prescription is current. Preserve the earlier record rather than rewriting the entire course retrospectively.
Inspect permissions and communication using test data. A receptionist may need appointment and task status while sensitive assessment detail remains within the appropriate clinical access. A generic portal role does not establish that this separation is configured correctly.
Review a small sample for unsupported 'review complete' states, stale investigation dates and unclear instructions after a change. These are documentation findings. They do not establish that the patient was eligible for treatment or that the clinic satisfies a particular regulatory programme.
A patient uploads a laboratory report before a planned isotretinoin review. The values are not flagged by the laboratory, but the patient also reports a new concern and an interruption in use. The team routes the account to the dermatologist and keeps the prescribing decision pending. The clinician records an assessment and an individual plan, then the current instructions are communicated. The workflow therefore preserves the difference between an available report and a completed clinical decision, without inventing a dose change or dismissing the concern.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
No. The dermatologist must consider the relevant clinical assessment, actual exposure, safety concerns and monitoring requirements. Report receipt and clinical review are separate events.
No. The cited MHRA update has UK jurisdiction. Indian clinicians need the applicable local requirements and product information. The guide uses the dated source for specific safety context and does not claim legal equivalence.
No. The January 2026 MHRA update removed that UK requirement while retaining other safety measures. This is a source-version distinction, not advice on the legal process for an Indian adolescent's treatment.
Not reliably without reconciling the actual product, instructions, changes and reported use. Preserve interruptions and uncertain information. Any calculation used by the clinician should expose its inputs and should not automatically select treatment.
Use the agreed communication arrangement and include only what is needed for the appointment or action. Avoid unnecessary reproductive or intimate symptom details. Clinical explanations should reach the intended patient through an appropriate channel.
Updated on . This is a follow-up documentation guide, not an isotretinoin prescribing protocol or legal compliance checklist. The specialist must determine eligibility, medicines, monitoring and the response to any safety concern. No independent clinical or legal review is claimed.
UK regulatory update dated 22 January 2026, accessed 25 October 2026. Supports the cited safety domains and correction of older UK second-prescriber wording. UK programme requirements are not described as Indian law.
Connect lesion descriptions, clinical photographs and site-specific skin treatment instructions in a practical workflow for Indian dermatology clinics.
Build a menstrual and symptom timeline, preserve diagnostic uncertainty and agree meaningful follow-up goals in Indian PCOS consultations.
Track pending clinic lab results with partial-report examples, corrected-version reviews, cover handovers and a six-order audit.
Show a fictional isotretinoin review in Bractis where a report is available but a new concern remains unresolved. Inspect clinical ownership, privacy and whether prescribing stays an explicit decision.
Request a clinic demo